new
infecti
diseas
sinc
outbreak
number
confirm
case
viru
reach
chines
mainland
midapril
case
die
among
cumul
confirm
case
hubei
provinc
wuhan
account
total
case
china
respect
top
prioriti
epidem
prevent
control
wang
et
al
report
novel
coronaviru
pneumonia
hospit
patient
clinic
characterist
wuhan
china
patient
common
symptom
includ
fever
fatigu
dri
cough
lymphopenia
prolong
prothrombin
time
elev
lactat
hydrogenas
occur
hospit
patient
spread
rapidli
throughout
china
guan
et
al
extract
data
patient
provinc
mainland
china
report
novel
coronaviru
pneumonia
patient
often
present
without
fever
mani
abnorm
radiolog
find
understand
novel
coronaviru
pneumonia
gradual
explor
process
prevent
control
protocol
novel
coronaviru
pneumonia
issu
gener
offic
nation
health
commiss
updat
version
still
specif
medicin
novel
coronaviru
pneumonia
categor
beta
genu
coronaviru
two
strainshuman
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
antivir
agent
recommend
prevent
control
protocol
novel
coronaviru
pneumonia
version
mainli
summar
antivir
therapi
merscov
sarscov
lopinavirritonavir
hiv
proteas
inhibitor
regist
therapeut
treatment
hiv
infect
lopinavir
screen
fdaapprov
compound
librari
inhibit
merscov
replic
lowmicromolar
rang
moreov
lopinavir
also
inhibit
replic
sar
coronaviru
human
coronaviru
arbidol
rna
synthesi
inhibitor
use
prophylaxi
treatment
influenza
b
sar
hepat
b
c
herpi
dengu
fever
rsv
abidol
identifi
effect
anticoronaviru
activ
vitro
therefor
efficaci
safeti
antivir
drug
need
confirm
clinic
trial
meanwhil
littl
inform
clinic
antivir
therapi
lopinavirritonavir
alon
combin
arbidol
patient
present
studi
retrospect
studi
medic
record
hospit
patient
evalu
antiviru
efficaci
lopinavirritonavir
alon
combin
arbidol
protocol
approv
ethic
committe
lishui
hospit
zhejiang
univers
ethic
review
clinic
regist
chines
clinic
trail
registri
case
materi
discharg
patient
collect
februari
march
lishui
central
hospit
zhejiang
china
wuhan
fourth
hospit
hubei
china
design
hospit
patient
diagnos
treat
accord
diagnosi
treatment
protocol
novel
coronaviru
pneumonia
issu
gener
offic
nation
health
commiss
inclus
criteria
hospit
patient
laboratoryconfirm
hospit
patient
treat
lopinavirritonavir
alon
combin
arbidol
antivir
therapi
exclus
criteria
hospit
patient
pneumonia
caus
pathogen
hospit
patient
nt
receiv
lopinavirritonavir
antivir
therapi
total
case
elig
particip
meet
inclus
criteria
exclus
criteria
patient
treat
lopinavirritonavir
mg
oral
twice
daili
identifi
grouplr
remaind
treat
lopinavirritonavir
mg
oral
twice
daili
combin
arbidol
mg
oral
three
time
day
identifi
grouplrar
elig
patient
receiv
support
treatment
necessari
supplement
oxygen
noninvas
invas
ventil
antibiot
agent
vasopressor
support
epidemiolog
demograph
clinic
laboratori
radiolog
characterist
treatment
outcom
data
collect
review
electron
medic
record
data
review
train
team
physician
inform
record
includ
demograph
data
clinic
present
medic
histori
laboratori
valu
ie
hematolog
paramet
biochem
paramet
time
viru
neg
chest
comput
tomograph
ct
scan
treatment
measur
hospit
stay
ie
antivir
therapi
corticosteroid
therapi
immunosuppress
therapi
clinic
classif
patient
carri
accord
diagnosi
treatment
protocol
novel
coronaviru
pneumonia
issu
gener
offic
nation
health
commiss
laboratori
test
result
group
admiss
time
day
primari
end
point
rate
cure
defin
hospit
patient
meet
discharg
criteria
discharg
criteria
follow
bodi
temperatur
back
normal
three
day
respiratori
symptom
improv
obvious
pulmonari
imag
show
obviou
absorpt
inflamm
nuclei
acid
test
neg
twice
consecut
respiratori
tract
sampl
sputum
nasopharyng
swab
sampl
interv
least
hour
secondari
end
point
hospit
stay
rate
rna
clearanc
time
nucleic
acid
turn
neg
symptom
disappear
admiss
result
time
nucleic
acid
test
respiratori
sampl
subject
last
test
nucleic
acid
neg
two
consecut
test
first
test
time
use
nucleic
acid
turn
neg
categor
variabl
describ
frequenc
rate
percentag
continu
variabl
describ
use
mean
median
inter
quartil
rang
iqr
valu
proport
categor
variabl
compar
use
test
although
fisher
exact
test
use
data
limit
continu
variabl
express
mean
sd
data
normal
distribut
mean
compar
use
depend
group
test
otherwis
data
nonnorm
distribut
express
median
inter
quartil
rang
use
mannwhitney
test
statist
analys
perform
use
spss
statist
packag
result
social
scienc
version
softwar
spss
inc
p
consid
significantli
differ
two
group
hospit
patient
discharg
februari
march
largest
number
patient
admit
wuhan
fourth
hospit
rest
patient
lishui
central
hospit
demograph
clinic
characterist
patient
shown
tabl
mean
age
grouplrar
year
rang
year
men
mean
age
grouplr
year
rang
year
men
differ
mean
age
sex
ratio
grouplrar
grouplr
patient
statist
signific
number
patient
level
age
statist
differ
grouplrar
ratio
ordinari
heavi
type
respect
ratio
ordinari
heavi
type
grouplr
patient
one
coexist
medic
condit
hypertens
coronari
heart
diseas
diabet
common
comorbid
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
antivir
efficaci
lopinavirritonavir
alon
combin
arbidol
treatment
hospit
patient
shown
tabl
grouplrar
patient
cure
discharg
hospit
patient
admit
transfer
icu
condit
aggrav
grouplr
cure
discharg
hospit
patient
transfer
icu
mortal
grouplrar
grouplr
respect
rate
rna
clearanc
grouplrar
grouplr
remov
patient
transfer
icu
die
grouplrar
time
nucleic
acid
turn
neg
day
hospit
stay
day
remov
die
case
grouplr
time
nucleic
acid
turn
neg
day
hospit
stay
day
patient
grouplrar
pulmonari
imag
manifest
patient
absorb
discharg
includ
less
absorpt
mark
improv
patient
absorb
discharg
grouplr
absorpt
pulmonari
imag
manifest
case
group
patient
chest
ct
find
worsen
grouplrar
case
worsen
grouplr
fever
cough
chest
tightnessd
main
symptom
hospit
patient
disappear
time
fever
cough
chest
tightnessd
grouplrar
day
day
grouplr
respect
tabl
comparison
primari
end
point
secondari
end
point
grouplrar
grouplr
variabl
lrar
lr
p
valu
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
clinic
laboratori
paramet
includ
white
blood
cell
neutrophil
lymphocyt
monocyt
creactiv
protein
procalcitonin
track
hospit
dynam
chang
laboratori
paramet
classifi
day
sinc
patient
admit
hospit
figur
signific
differ
clinic
laboratori
paramet
grouplrar
grouplr
mean
white
blood
cell
neutrophil
count
normal
rang
two
group
level
lymphocyt
count
decreas
two
group
next
lower
normal
limit
minimum
day
admit
hospit
two
group
low
level
lymphocyt
day
hospit
signific
differ
contrari
level
monocyt
next
upper
normal
limit
level
inflammatori
biomark
creactiv
protein
mark
increas
earli
hospit
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
two
group
gradual
declin
time
hospit
mean
creactiv
protein
higher
grouplr
grouplrar
mean
valu
procalcitonin
slightli
higher
upper
normal
limit
signific
differ
two
group
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
lymphocyt
damag
immun
system
diseas
crp
use
gaug
inflamm
trend
valu
hospit
patient
increas
slightli
admiss
decreas
gradual
suggest
host
defens
invad
pathogen
well
inflammatori
respons
pct
sensit
indic
bacteri
infect
profil
pct
level
rel
stabl
markedli
rais
trial
sever
limit
first
studi
retrospect
analysi
random
futur
prospect
studi
overcom
defect
second
case
studi
accord
studi
data
lopinavirritonavir
treatment
sever
case
conclud
sampl
size
need
subject
evalu
efficaci
lopinavirritonavir
combin
abidor
better
wors
singl
drug
treatment
lopinavirritonavir
third
age
gender
two
group
balanc
small
sampl
howev
signific
differ
group
stratif
gender
age
futur
increas
number
research
sampl
improv
test
effici
enhanc
credibl
research
result
final
result
studi
suggest
overal
treatment
effect
well
difficult
judg
antivir
effect
use
cure
rate
viru
turn
neg
rate
primari
endpoint
therefor
may
feasibl
clinic
practic
find
suitabl
popul
primari
endpoint
evalu
therapeut
effect
antivir
drug
evalu
whether
reduc
mortal
sever
ill
popul
conclus
found
lopinavirritonavir
alon
combin
arbidol
treatment
significantli
increas
cure
rate
reduc
hospit
time
rais
viru
neg
rate
diminish
viru
neg
time
hospit
patient
preliminari
result
could
inform
futur
trial
evalu
medic
treatment
infect
whether
lopinavirritonavir
combin
antivir
drug
might
enhanc
antivir
effect
improv
clinic
outcom
need
clinic
observ
data
use
support
find
studi
avail
correspond
author
upon
request
author
declar
conflict
interest
